Ocugen, Inc. has priced $115 million of 6.75% convertible senior notes due 2034 in a private offering to qualified institutional buyers. The company expects to net about $99.5 million, or up to $112.6 million if the initial purchaser exercises an option to buy more. Ocugen plans to use approximately $32.7 million of the proceeds to repay an outstanding loan and related fees, with the remainder going to general corporate purposes. The notes bear interest semi-annually, mature in 2034, and have conversion features allowing holders to convert into Ocugen common stock starting in 2027, subject to conditions.
Basel Medical Group Ltd announced it has regained compliance with Nasdaq's minimum bid price rule after its share price stayed at or above $1.00 for 10 consecutive business days ending July 7, 2026. The company was previously notified in January 2026...
The global wax market, valued at $11.26 billion in 2025, is projected to grow to $16.65 billion by 2035 at a CAGR of 3.99%. Growth is fueled by rising demand in packaging, cosmetics, candle making, adhesives, and industrial uses, with natural waxes l...
BingX, a major crypto exchange, introduced the BingX Visa Debit Card in partnership with Wirex, allowing users to spend digital assets globally through Visa's payment network. The card supports purchases, ATM withdrawals, and automatic currency conve...
Backpack has introduced the first-ever 24/7 trading platform for real U.S. equities, allowing international investors to buy and sell stocks like SpaceX, Micron, and SanDisk around the clock. Unlike synthetic derivatives, these are actual equities wi...
Independent proxy advisory firms, including ISS, recommend Equinox Gold shareholders vote in favor of the proposed merger with Orla Mining, which aims to create a leading North American gold producer. The combined company is expected to produce 1.1 m...
